- In March 2024, Lantheus Holdings, Inc. received U.S. Food and Drug Administration (FDA) approval for a supplemental new drug application (sNDA) for its ultrasound contrast agent, DEFINITY, allowing its use in pediatric patients with suboptimal echocardiograms. While primarily an ultrasound agent, this highlights a broader trend of expanding contrast media applications across patient populations and underscores the industry's commitment to improving diagnostic capabilities for a wider range of clinical needs
- In February 2024, Bayer continued to advance its radiology portfolio, presenting new clinical results for investigational contrast agents and highlighting its commitment to innovation in radiology AI and digital solutions. Bayer's strategy focuses on improving patient outcomes and supporting radiologists with everyday clinical tasks through its comprehensive portfolio of contrast media for CT, X-ray, and MRI, along with devices for their precise administration
- In December 2024, Bracco Diagnostics Inc., a leading global company in diagnostic imaging, showcased its cutting-edge innovations at RSNA 2024, including advancements in contrast-enhanced ultrasound and AI-powered contrast enhancement solutions for MR imaging. This demonstrates Bracco's commitment to continuous innovation across imaging modalities and its focus on precision medicine, contributing to enhanced diagnostic capabilities and more efficient clinical workflows
